[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:immunoglobulin-g4-related-disease":3},{"name":4,"total":5,"trials":6,"biomarkers":22,"states":23},"Immunoglobulin G4 related disease",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07190196","A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease",[11],"Phase 3","RECRUITING","2026-08-03T01:00:36.258449Z","2026-07-30T01:46:14.417526Z",{"nct_id":16,"title":17,"phases":18,"status":19,"updated_at":20,"content_modified":21},"NCT02422875","Comparative Autoantibody and Immunologic Cell Marker Study",[],"ENROLLING_BY_INVITATION","2026-08-03T03:51:20.345996Z","2026-06-16T05:54:07.952442Z",[],[]]